A Billionaire-Backed Startup Wants to Grow 'Organ Sacks' to Replace Animal Testing
Animal testing has long been a contentious issue, with many experts arguing that it is not only inhumane but also inefficient. As the US government phases out the use of animal experimentation, a biotech startup has proposed an innovative solution: nonsentient "organ sacks." These structures would contain all the typical organs, except a brain, rendering them unable to think or feel pain. The company behind this idea, R3 Bio, aims to create human versions of these organ sacks that could be used as a source of tissues and organs for people in need.
R3 Bio's proposal is gaining traction, with Immortal Dragons, a Singapore-based longevity fund, investing in the company. The fund's CEO, Boyang Wang, believes that replacement is a more effective strategy than repair when it comes to treating diseases or regulating the aging process. By creating nonsentient, headless bodyoids for humans, R3 Bio hopes to provide a reliable source of organs for transplantation.
The company is currently working on creating monkey organ sacks, which would allow for more scalable testing. This is particularly important, as new drugs are often tested in monkeys before being given to human participants in clinical trials. However, the use of monkeys is becoming increasingly expensive and difficult, with China banning the export of nonhuman primates in 2020. As a result, the US Centers for Disease Control and Prevention is winding down monkey research, and R3 Bio's proposal could provide a much-needed alternative.
R3 Bio's innovative approach to replacing animal testing has significant implications for the biotech industry. While it may take time to develop and refine this technology, it could ultimately lead to more efficient and humane testing methods. As Nigeria's biotech sector continues to grow, it will be interesting to see how this technology is adapted and applied in African contexts. Companies like Andela, which focuses on developing tech talent, could potentially partner with biotech startups to accelerate innovation in this area.
